ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease Activity"

  • Abstract Number: 2531 • 2015 ACR/ARHP Annual Meeting

    Hematologic Disorder during Pregnancy Associated with Adverse Pregnancy Outcomes Among Women with Systemic Lupus Erythematosus

    Sara K. Tedeschi1, Hongshu Guan2, Alexander Fine2, Bing Lu1, Karen H. Costenbader1 and Bonnie Bermas1, 1Rheumatology, Brigham & Women's Hospital, Boston, MA, 2Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Previous studies have found a relationship between overall systemic lupus erythematosus (SLE) activity and adverse pregnancy outcomes. We sought to investigate whether specific types…
  • Abstract Number: 2663 • 2015 ACR/ARHP Annual Meeting

    Evaluation of Anti-Cyclic Citrullinated Peptide Autoantibody Levels in Clinical Practice and Its Association with Disease Activity

    E Alemao1, KK Gandhi1, C Iannaccone2, M Frits2, JS Coblyn2, N Shadick2 and Michael Weinblatt2, 1Bristol-Myers Squibb, Princeton, NJ, 2Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Testing for anti-citrullinated peptide antibodies (ACPA) is included in the 2010 ACR classification criteria for RA. ACPA concentration, beyond ACPA positivity, is indicative of…
  • Abstract Number: 3045 • 2015 ACR/ARHP Annual Meeting

    Anti-Alpha-Enolase Antibodies in Behçet’s Disease: A Marker of Articular Disease Activity?

    Leandro L. Prado, Celio R. Gonçalves, Vilma S. T. Viana, Eloisa Bonfá and Carla G.S. Saad, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Diagnosis of Behçet´s disease (BD) is challenging because is based solely on clinical features. Articular involvement in this disease may mimic other diagnosis such…
  • Abstract Number: 169 • 2015 ACR/ARHP Annual Meeting

    Ultrasonographic Signs of Inflammation of Metatarsophalangeal Joints in Rheumatoid Arthritis Patients Who Are Treated to Target

    Myrthe van der Ven1, David F. Ten Cate2, Andreas Gerards3, Johannes Jacobs4, Nanno Swen5, M.H. de Jager6, Natalja Basoski7, Cees Haagsma8, Mieke Hazes1 and J.J. Luime1, 1Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 2Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 3Rheumatology, Vlietland Hospital, Schiedam, Netherlands, 4Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 5Rheumatology, Medical Center Alkmaar, Alkmaar, Netherlands, 6Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, 7Rheumatology, Maasstadziekenhuis, Rotterdam, Netherlands, 8Rheumatology, Ziekenhuisgroep Twente, Almelo, Netherlands

    Background/Purpose: The feet are often involved in rheumatoid arthritis (RA), but physical examination of the metatarsophalangeal (MTP) joints to detect arthritis is challenging especially in…
  • Abstract Number: 533 • 2015 ACR/ARHP Annual Meeting

    The Interferon Gene Signature in Early Rheumatoid Arthritis Demonstrates No Significant Association with Disease Activity

    Faye A H Cooles1, Amy E. Anderson2, Catharien Hilkens3 and John D Isaacs4, 1Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne, United Kingdom, 2Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, 3Musculoskeletal Research Group, Newcastle University, Newcastle Upon Tyne, United Kingdom, 4Newcastle University and the Freeman Hospital, Newcastle-upon-Tyne, United Kingdom

    Background/Purpose: An interferon-α gene signature (IGS) has been demonstrated in a number of rheumatological conditions, including rheumatoid arthritis (RA) where it is present in about…
  • Abstract Number: 735 • 2015 ACR/ARHP Annual Meeting

    Belimumab Reduces the Frequency of Flares and Prevents Damage Progression in SLE Patients: Experience in a Clinical Practice Setting

    Luca Iaccarino1, Silvano Bettio1, Rossella Reggia2, Margherita Zen3, Micol Frassi2, Laura Andreoli2, Linda Nalotto1, Mariele Gatto1, Lara Pea2, Nicola Bassi1, Maddalena Larosa1, Alessandra Zanola2, Leonardo Punzi4, Angela Tincani2 and Andrea Doria1, 1Department of Medicine-DIMED, University of Padova, Padova, Italy, 2Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 3Division of Rheumatology, University of Padova, Padova, Italy, 4Unit of Rheumatology, University of Padova, Padova, Italy

    Background/Purpose: To investigate the efficacy and safety of belimumab in patients affected with active systemic lupus erythematosus (SLE) refractory to standard therapy. Methods: Fifty-eight patients,…
  • Abstract Number: 1550 • 2015 ACR/ARHP Annual Meeting

    Flares of Disease Activity As Risk Factor for the Occurrence of Myocardial Infarction in Patients with Rheumatoid Arthritis

    Esmee Bakker1, Pauline Geuijen2, Beata Radovits1, Delia Popa-Diaconu1, Calin Popa1, Elke Arts1, Alfons A. den Broeder3 and Jaap Fransen1, 1Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, 2Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 3Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands

    Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular diseases (CVD). The underlying mechanism is partly explained by the inflammation process in both…
  • Abstract Number: 2069 • 2015 ACR/ARHP Annual Meeting

    High Interferon Gene Signature Is Associated with Increased Disease Activity, Reduced Complement C3 and C4, and Increased Oral Corticosteroid Use in Systemic Lupus Erythematosus (SLE)

    K Ranade, L Wang, P Brohawn, W Greth, J Drappa and G Illei, MedImmune, Gaithersburg, MD

    Background/Purpose: Increased expression of genes inducible by type 1 interferons has been observed in a subset of patients with systemic lupus erythematosus (SLE). Oral corticosteroids…
  • Abstract Number: 2532 • 2015 ACR/ARHP Annual Meeting

    Disease Activity in Women with Systemic Lupus Erythematosus during Pregnancy and the First Year Post Partum

    Carina Gotestam Skorpen1,2, Johan Skomsvoll3, Inge-Margrethe Gilboe4, Stian Lydersen5 and Marianne Wallenius3, 1Dept of Neuroscience, Norwegian University of Science and Technology (NTNU), Trondheim, Norway, 2Dept of Rheumatology, Trondheim University Hospital, Norwegian National Advisory Unit on Pregnancy and Rheumatic Diseases, Trondheim, Norway, 3Dept of Rheumatology, Trondheim University Hospital, National Advisory Unit on Pregnancy and Rheumatic Diseases, Trondheim, Norway, 4Revmatologisk avdeling seksjon, Oslo universitetssykehus HF, Rikshospitalet, Oslo, Norway, 5Regional Center for the health of children and adolescents, Norwegian University of Science and Technology (NTNU), Trondheim, Norway

    Disease Activity in women with SLE during pregnancy and the first year post partumBackground/Purpose: Disease activity measured by validated methods has been sparsely examined during…
  • Abstract Number: 2672 • 2015 ACR/ARHP Annual Meeting

    Determinants of Patient- Physician Discordance in Assessment of Global Disease Activity in Latinos with Rheumatoid Arthritis in the United States

    George A. Karpouzas1, Taylor Draper2, Elizabeth Hernandez1 and Sarah Ormseth1, 1Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, 2Psychology, Loma Linda University, Loma Linda, CA

    Background/Purpose: Patients and physicians often differ in their perceptions of disease activity in Rheumatoid arthritis (RA) as described by patients' and evaluators' global assessments (PGA…
  • Abstract Number: 3058 • 2015 ACR/ARHP Annual Meeting

    NMR-Based Metabolomics Provides New Insights into the Inflammatory Processes in Takayasu Arteritis

    Ramnath Misra1, Anupam Guleria2, Durga Prasanna Misra1, Avadesh Pratap3, Durgesh Dubey4, Atul Rawat4, Smriti Chaurasia3, C L Khetrapal4, Dinesh Kumar4 and Paul Bacon5, 1Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Centre of Biomedical Research, Lucknow, India, 3S.G.P.G.I.M.S, Department of Clinical Immunology, Lucknow, India, 4Centre for Biomedical Research, Lucknow, India, 5Rheumatology, Birmingham Universit, Birmingham, United Kingdom

    Background/Purpose: Takayasu Arteritis (TA), a large vessel disease of unknown aetiology, is the orphan of the inflammatory vasculitides with no evidence base for therapy. It…
  • Abstract Number: 2 • 2015 ACR/ARHP Annual Meeting

    The Neutrophil Protein S100A12 Has Stronger Associations with a Comprehensive Ultrasound Score of Synovitis Than Vascular Endothelial Growth Factor in a Longitudinal Study of Rheumatoid Arthritis Patients

    Hilde Haugedal Nordal1,2 and Hilde Berner Hammer3, 1Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, 2Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, 3Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose: S100A12, a neutrophil protein, has proinflammatory effects on immune cells and can activate endothelial cells. The mechanism of action suggests vascular endothelial growth factor…
  • Abstract Number: 171 • 2015 ACR/ARHP Annual Meeting

    Serum Calprotectin Levels Correlate with Ultrasonographic Synovitis in Rheumatoid Arthritis Patients

    Jana Hurnakova1, Jakub Zavada1, Petra Hanova1, Hana Hulejová1, Martin Klein1, Herman F Mann1, Olga Sleglova1, Marta Olejarova1, Šárka Forejtová1, Olga Ruzickova1, Martin Komarc2, Jiri Vencovsky1, Karel Pavelka1 and Ladislav Senolt1, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 2Institute of Biophysics and Informatics of the First Faculty of Medicine, Charles University, Prague, Czech Republic

    Background/Purpose: Calprotectin (S100A8/9, MRP8/14) has been demonstrated as a promising biomarker of clinical and laboratory disease activity in rheumatoid arthritis (RA). In addition, two small…
  • Abstract Number: 535 • 2015 ACR/ARHP Annual Meeting

    Taurine As a Biomarker for Prediction of Response to Biologic Therapy in Rheumatoid Arthritis

    Soshi Takahashi1, Jun Saegusa2, Ikuko Naka1, Kosaku Tsuda1, Takaichi Okano1, Kengo Akashi1, Miwa Nishida1, Keisuke Nishimura2, Sho Sendo2, Yo Ueda1, Akira Onishi3, Yoshinori Kogata2, Goichi Kageyama2 and Akio Morinobu2, 1Department of Rheumatology, Kobe University Hospital, Kobe, Japan, 2Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 3Rheumaology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan

    Background/Purpose: To identify a serum biomarker for prediction of the response to biologics (Bio) in patients with rheumatoid arthritis (RA), we performed serum metabolomics analysis…
  • Abstract Number: 757 • 2015 ACR/ARHP Annual Meeting

    The Ratio Between TNF-a and P-Albumin – a Suggested Measure of Disease Activity in SLE

    Susanna Eketjäll1, Helena Idborg2, Johanna Gustafsson3, Agneta Zickert2, Marika Kvarnstrom4, Vilija Oke5, Susanne Pettersson4, Per Johan Jakobsson4, Iva Gunnarsson4 and Elisabet Svenungsson4, 1Department of Clinical Neuroscience, Karolinska Institutet, Solna, AstraZeneca Translational Sciences Centre, Science for Life Laboratory, Personal Healthcare and Biomarkers, Stockholm, Sweden, 2Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 3Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 4Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 5Department of medicine, Unit of Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: There is presently no consensus on how to best measure disease activity in systemic lupus erythematosus (SLE). Available validated measures, such as SLE Disease…
  • « Previous Page
  • 1
  • …
  • 82
  • 83
  • 84
  • 85
  • 86
  • …
  • 102
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology